MedImmune And NGM To Collaborate On Drugs To Mimic Benefits Of Bariatric Surgery
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies will partner to discover and develop peptide therapeutics based on hormones secreted in the gastrointestinal tract. MedImmune hopes this approach will be safer and more broadly applicable than bariatric surgery.